IPSS-M Calculator for Myelodysplastic Syndromes (MDS)
The Molecular International Prognostic Scoring System (IPSS-M) helps stratify risk in patients with Myelodysplastic Syndromes by incorporating clinical, cytogenetic, and molecular data. This calculator provides an estimate based on published criteria.
Disclaimer: This tool is for informational purposes only and should not replace professional medical advice. Consult with a qualified healthcare provider for diagnosis and treatment decisions.
Understanding the IPSS-M Score
The IPSS-M score provides a more refined risk assessment for Myelodysplastic Syndromes (MDS) compared to previous systems by integrating molecular data. A lower score generally indicates a better prognosis, while a higher score suggests a higher risk of disease progression or transformation to acute myeloid leukemia (AML).
The score is calculated by summing points assigned to various clinical and molecular parameters:
- Clinical Variables: Hemoglobin level, platelet count, bone marrow blast percentage, and IPSS-R cytogenetic risk category.
- Molecular Variables: Presence of specific gene mutations, such as SF3B1 (potentially favorable), TP53 multi-hit (adverse), and a panel of other somatic mutations (adverse, with a maximum of three contributing to the score from the designated list).
The total score then places the patient into one of six risk categories, from Very Low to Very High. These categories help guide discussions about prognosis and potential treatment strategies. It’s important to discuss these results with a hematologist specialized in MDS.